11，Sollinger HW. Update on preclinical and clinical experience with mycop henolate mofetil. Transplantation Proceedings 1996,29 Suppl 1:24-29. 被引量：1
22，Groth CG. For the European MMF cooperative study group. The European e xperience with mycophenolate mofetil. Transplantation Proceedings 1996,28 Suppl 1:30-33. 被引量：1
35，Corna D, Morigi M, Facchinetti D, et al. Mycophenolate myfetil limit r enal damage and prolongs life in murin lupis autoimmune disease. Kidney Int 1997 ,51:1589-1589.. 被引量：1
46，Willam A. Briggs, Michael J. Chor, Paul J. Scheel, Jr Successful mycop henolate mofetil treatment of glomerular disease. Am J Kidney Dis 1998,31:213-2 17. 被引量：1
6Combes B, Stastny P. Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane. Lancet, 1971,2: 234～ 6. 被引量：1
7Lai CL, Liaw YF, Lewns NW, et al. Genotypic resistance to lamivudine in a prospective, place-controlled multicentre study in Asia of Lamivudine therapy for chronic hepatitis B infection:incidence, kineties of emergence, and correlation with disease parameters. Hepatology, 1997, 2654: 259～60. 被引量：1
8Ponticelli C, Passerini P. Conventional treatment of idiopathic nephrotic syndrome and membra-nousnephropathy in adults. Cli Nephrol, 1999,35:516-517. 被引量：1
9Briggs WA, Choi M J, Scheel PJ, et al. Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis, 1998,31(2):213-215. 被引量：1
